Surgical Management and Mechanical Circulatory Support in High ...
Pulmonary Arterial Hypertension Market Is Estimated To Be US$ 12.2 Billion By 2032 And Is Anticipated To Register A CAGR Of 5.5%. – By PMI
Increased clinical trials for the development of therapies to treat pulmonary arterial hypertension and the availability of generic medications at reasonable prices as a result of increasing patent expiration are driving the growth of the pulmonary arterial hypertension market, with the oral segment expected to lead the market for PAH between 2022 and 2032.
Covina, Oct. 18, 2023 (GLOBE NEWSWIRE) -- How is PAH diagnosed?
Pulmonary Arterial Hypertension (PAH) is the form of broader condition called as pulmonary hypertension, where the increased pressure in vessels are caused by obstruction in small arteries of lungs. They are caused by high blood pressure in lungs arteries due to connective tissue disease, congenital heart disease and others.
Rapidly increased geriatric population coupled with rising incidence of chronic diseases across globe has become major contribution in market growth. Presence of major players and well-planned reimbursement structure has further, facilitated the demand for target market growth. Further, increased awareness among people and robust healthcare infrastructure is expected to boost the demand for Pulmonary Arterial Hypertension market growth over the forecast period.
Recent Key Development:
In September 2022, after getting approval from U.S. FDA (Food and Drug Administration) the Lupin has launched its new 'Sildenafil' oral suspension in U.S. Market for treating pulmonary arterial hypertension. The new launched drug is generic equivalent of Viatris Specialty LLC's Revatio.
Get a sneak peek of the samply copy of the report dynamics @
https://www.Prophecymarketinsights.Com/market_insight/Insight/request-sample/5175
Pulmonary Arterial Hypertension Market – Report Scope:
Attributes
Details
Pulmonary Arterial Hypertension Market Value (2022)
US$ 7.3Bn
Pulmonary Arterial Hypertension Market Projected Value (2032)
US$ 12.2Bn
Pulmonary Arterial Hypertension Market CAGR (2022 – 2032)
5.5%
Pulmonary Arterial Hypertension Market Assessment
Pulmonary Arterial Hypertension Market segmentation:
By Drug Class - PDE-5 Inhibitors, Endothelin Receptor Antagonists (ERAs), SGC Stimulators, Prostacyclin & Prostacyclin Analogs
By Type - Generics, Branded
By Route of Administration - Inhalational, Intravenous/Subcutaneous, Oral
Story continues
Key Players of Pulmonary Arterial Hypertension Market:
United Therapeutics Corporation
Johnson & Johnson
Bayer
Gilead Sciences Inc.
GlaxoSmithKline
Lupin Pharmaceuticals Inc.
Novartis
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries, Inc.
Viatris Inc.
To know more about Pulmonary Arterial Hypertension Market, visit PDF copy of the report @ https://www.Prophecymarketinsights.Com/market_insight/Insight/request-pdf/5175
Pulmonary Arterial Hypertension Market Dynamics
The chronic pulmonary hypertension market is influenced by various factors, including a growing prevalence of pulmonary hypertension, advancements in diagnostic and treatment options, and increasing awareness of the condition among healthcare professionals and patients. Additionally, pharmaceutical companies are actively engaged in research and development to introduce innovative therapies for chronic pulmonary hypertension, driving competition and potentially expanding treatment options. Market dynamics are also impacted by regulatory changes and healthcare reimbursement policies, which can affect access to treatment for patients. Overall, the chronic pulmonary hypertension market is evolving with a focus on improving patient outcomes and quality of life.
Scope of the Pulmonary Arterial Hypertension Market Report
A comprehensive Chronic Pulmonary Hypertension Market Report would encompass an analysis of the current market landscape, including prevalence and incidence statistics, market trends, and key players. It should also provide insights into the competitive landscape, emerging therapies, and technological advancements. Furthermore, the report should cover regulatory factors and reimbursement policies that impact the market. A holistic report would offer projections for market growth, potential challenges, and opportunities, aiding stakeholders in making informed decisions regarding investments, research, and business strategies in the chronic pulmonary hypertension sector.
Impact of COVID-19 Pandemic on Pulmonary Arterial Hypertension Market Growth:
The COVID-19 pandemic had a mixed impact on the Pulmonary Arterial Hypertension (PAH) market. On one hand, it temporarily disrupted healthcare services and clinical trials, affecting diagnosis and treatment. On the other hand, it accelerated telehealth adoption and increased awareness of respiratory conditions, potentially driving demand for PAH treatments. The long-term consequences are still evolving, with a focus on innovation in remote patient monitoring and drug development to adapt to changing healthcare dynamics.
Analyst View:
Growing prevalence of pulmonary arterial hypertension across globe has contributed in target market growth. Rising government initiatives across globe to prevent this disease is expected to fuel the demand for market growth. Presence of major players and growing market consolidation activities is likely to propel Pulmonary Arterial Hypertension market growth.
FAQs
What is the current size and value of the Pulmonary Arterial Hypertension market?
What are the major drivers of growth in the PAH market?
What are the key challenges and barriers to entry in the PAH market?
Which regions or countries have the highest prevalence of PAH, and how does this impact the market?
Who are the major players in the PAH pharmaceutical and medical device market, and what are their market shares?
Conclusion:
The pulmonary arterial hypertension (PAH) market is characterized by ongoing research and development efforts to introduce innovative therapies that improve patient outcomes. With the emergence of novel treatment options and a growing focus on early diagnosis, the PAH market shows promise for continued growth and enhanced patient care in the coming years. However, challenges such as high treatment costs and limited access to therapies remain significant hurdles to address for the sustained progress of this market.
Request for Customization on this Report as per your requirements
https://www.Prophecymarketinsights.Com/market_insight/Insight/request-customization/5175
Browse other research published by Prophecy market insights:
About Us -
Blog: www.Prophecyjournals.Com
Follow us on:
LinkedInTwitterFacebookYouTube
CONTACT: Shweta R Prophecy Market Insights U.S.: +1 860 531 2574 APAC: +917775049802 Email- sales@prophecymarketinsights.Com Web: www.Prophecymarketinsights.ComHypertension News
Mar. 14, 2023 — Scientists have found that inhibiting a gene essential to making DNA can significantly reduce the destructive cell proliferation and disease progression in pulmonary ...
Mar. 1, 2023 — High blood pressure disorders during pregnancy are associated with an increased risk of thinking problems later in life, according to a study. Researchers found that those with these disorders had a ...
Feb. 28, 2023 — A new device that calms overactive kidney nerves with ultrasound consistently lowered blood pressure in patients with uncontrolled hypertension, researchers have ...
Feb. 8, 2023 — In a new analysis involving adolescents living in London, exposure to higher levels of the pollutant nitrogen dioxide was associated with lower systolic blood pressure, while exposure to higher ...
Feb. 8, 2023 — Certain complications during pregnancy bring an increased risk of heart disease later on. However, there is still much to learn about how arteriosclerosis develops between pregnancy and heart disease ...
Jan. 16, 2023 — Doctors have used a new type of CT scan to light up tiny nodules in a hormone gland and cure high blood pressure by their removal. The nodules are discovered in one-in-twenty people with high blood ...
Dec. 21, 2022 — Drinking two or more cups of coffee a day was associated with twice the risk of death from cardiovascular disease among people with severe hypertension compared to non-coffee drinkers, in a study of ...
Dec. 13, 2022 — A new study suggests lipoprotein(a) cholesterol may affect relationship between hypertension and cardiovascular disease ...
Dec. 8, 2022 — A three-month pilot study of patients with hypertension demonstrates that adding yoga to a regular exercise training regimen supports cardiovascular health and wellbeing and is more effective than ...
Dec. 6, 2022 — Teens with Type 1 diabetes who took bromocriptine, a medication usually prescribed to treat Parkinson's disease, had lower blood pressure after one month of treatment compared to those who did ...
Dec. 5, 2022 — Engineers have designed a system to remotely measure blood pressure by filming a person's forehead and extracting cardiac signals using artificial intelligence ...
Nov. 15, 2022 — An analysis of more than 2,400 women who did not have high blood pressure while pregnant found that about 1 in 10 were diagnosed with high blood pressure in the year after childbirth. Almost a ...
Nov. 7, 2022 — A new drug called Baxdrostat has been shown to significantly reduce high blood pressure (hypertension) in patients who may not respond to current treatments for the condition, according to results ...
Nov. 4, 2022 — People with elevated blood pressure saw improvement after 12 weeks of a telehealth support program, with or without support from a dietitian, a new study ...
Nov. 3, 2022 — Even after chronic hepatitis C has been cured, portal hypertension remains the major factor driving the development of complications in advanced liver disease. Researchers have shown that the ...
Nov. 1, 2022 — Adults with hypertension saw a small, but consequential, rise in their blood pressure levels during the first eight months of the COVID-19 pandemic, while the number of times they had their blood ...
Oct. 26, 2022 — A global study of over 28,000 people has provided the strongest evidence to date that lowering blood pressure in later life can cut the risk of ...
Oct. 12, 2022 — Researchers have shown that while intensive blood pressure control was beneficial to SPRINT participants' health during the trial, the benefits for cardiovascular mortality went away after ...
Oct. 5, 2022 — Procyanidins are a class of polyphenols (plant metabolites) that are abundantly found in nature. The B-type procyanidins are one of the most commonly consumed catechin oligomers in the human diet. ...
Oct. 4, 2022 — The kidneys are often the unsung heroes in maintaining healthy blood pressure, filtering 180 liters of fluid and a pound of salt every day to keep levels in check. But new research by geneticists and ...
Tuesday, March 14, 2023
Wednesday, March 1, 2023
Tuesday, February 28, 2023
Wednesday, February 8, 2023
Monday, January 16, 2023
Wednesday, December 21, 2022
Tuesday, December 13, 2022
Thursday, December 8, 2022
Tuesday, December 6, 2022
Monday, December 5, 2022
Tuesday, November 15, 2022
Monday, November 7, 2022
Friday, November 4, 2022
Thursday, November 3, 2022
Tuesday, November 1, 2022
Wednesday, October 26, 2022
Wednesday, October 12, 2022
Wednesday, October 5, 2022
Tuesday, October 4, 2022
Monday, October 3, 2022
Thursday, September 29, 2022
Friday, September 23, 2022
Tuesday, September 20, 2022
Wednesday, September 7, 2022
Tuesday, September 6, 2022
Friday, September 2, 2022
Monday, August 29, 2022
Thursday, August 25, 2022
Wednesday, August 3, 2022
Wednesday, July 27, 2022
Tuesday, July 26, 2022
Monday, July 25, 2022
Thursday, July 21, 2022
Friday, July 15, 2022
Wednesday, July 13, 2022
Monday, July 11, 2022
Thursday, June 23, 2022
Monday, June 13, 2022
Tuesday, June 7, 2022
Friday, June 3, 2022
Wednesday, June 1, 2022
Thursday, May 26, 2022
Monday, May 23, 2022
Monday, May 16, 2022
Thursday, May 12, 2022
Monday, May 9, 2022
Friday, May 6, 2022
Thursday, May 5, 2022
Monday, April 25, 2022
Friday, April 22, 2022
Monday, April 4, 2022
Thursday, March 31, 2022
Monday, March 28, 2022
Thursday, March 17, 2022
Thursday, March 10, 2022
Wednesday, March 2, 2022
Wednesday, February 23, 2022
Tuesday, February 22, 2022
Monday, February 14, 2022
Wednesday, February 9, 2022
Tuesday, February 1, 2022
Wednesday, January 12, 2022
Tuesday, January 4, 2022
Tuesday, December 21, 2021
Wednesday, December 15, 2021
Wednesday, December 8, 2021
Tuesday, December 7, 2021
Monday, December 6, 2021
Tuesday, November 23, 2021
Wednesday, November 17, 2021
Thursday, November 11, 2021
Monday, October 4, 2021
Tuesday, September 28, 2021
Monday, September 27, 2021
Monday, September 20, 2021
Monday, September 13, 2021
Monday, August 30, 2021
Thursday, August 19, 2021
Thursday, August 12, 2021
Tuesday, August 3, 2021
Monday, July 26, 2021
Thursday, July 15, 2021
Wednesday, June 23, 2021
Monday, June 21, 2021
Tuesday, June 15, 2021
Monday, June 14, 2021
Wednesday, June 2, 2021
Monday, May 31, 2021
Monday, May 17, 2021
Thursday, May 6, 2021
Tuesday, May 4, 2021
Which Illnesses Could Be An Early Sign Of Diabetes?
Type 2 diabetes is a chronic disorder marked by high blood glucose levels. This could be due either to insufficient insulin levels, insulin resistance, or both factors.
Research shared at the 2023 Annual Meeting of The European Association for the Study of Diabetes in Hamburg, Germany suggests that it might be easier to track early type 2 diabetes development in some individuals.
The insights, also published in Diabetes Therapy, came from an analysis based on data from the Diabetes Alliance for Research in England (DARE) study.
Study first author Dr. Adrian Heald of Manchester University, United Kingdom said in a press release: "These findings hint at the potential for type 2 diabetes to be diagnosed earlier, and we hope that the distinct clinical trajectory could become a predictive tool for people at risk of the disease."
Type 2 diabetes often develops alongside other conditions. The present study sifted through pre- and post-type 2 diabetes diagnosis clinical histories for further insights into causes and trajectories for related health conditions.
Dr. Heald and his team said "[t]he main goal of this study was to detect any temporal continuums of comorbidity or clinical indications which predate the onset of diabetes and to document the important health difficulties in persons on a time continuum spanning from before and after a clinical diagnosis of type 2 diabetes."
The researchers say that the set of causes behind type 2 diabetes are yet undetermined, but onset is "clearly linked to chronic overweight and obesity and a sedentary lifestyle."
The causal link associations between type 2 diabetes and multimorbidity — several coexisting health conditions — remain unknown as well.
Previous studies suggest that environmental variables, including lack of physical activity and access to healthy foods, may promote the disease's emergence.
The U.K. Researchers turned to the DARE study to find the most prevalent clinical conditions in people with type 2 diabetes.
They searched through data on 1,932 adults with and without type 2 diabetes, matched by age and gender, over a period covering 50 years – 25 years pre-diagnosis and 25 years post-diagnosis.
The researchers reviewed health records on 1,196 people who eventually received a type 2 diabetes diagnosis and 736 who did not. The average age at diagnosis was 53 years.
The analysis revealed that several common illnesses increased consistently in the years preceding diagnosis. These included hypertension, respiratory tract infections, cardiovascular conditions, asthma, and eye, nose, and throat infections.
The study authors saw that immediately prior to being diagnosed with type 2 diabetes, over one in three people had high blood pressure and respiratory tract infections. Approximately one in five experienced a heart condition or eye, nose, and throat infection, and one in 10 had asthma.
On the other hand, only one in 20 people who did not develop type 2 diabetes were diagnosed with these illnesses. Respiratory tract infections followed a different trajectory, being experienced by one in 10 of these individuals.
After a type 2 diabetes diagnosis, cases of hypertension, chronic kidney disease (CKD), retinopathy, and infections spiked for 15 years before leveling off. Heart conditions and asthma followed this course as well.
The U.K. Researchers believe this suggests that subacute inflammation, caused by genetics or comorbidities, "may serve as a precursor to the later onset of [type 2 diabetes]."
The study's findings may also indicate that type 2 diabetes is not necessarily inevitable.
"Understanding the long-term clinical history of type 2 diabetes years before diagnosis means that, in the future, people could have the time to make lifestyle changes to prevent this life-changing disease from arising," Dr. Heald said.
Dr. Heald and his team noted that several illnesses tend to co-occur with type 2 diabetes.
Health experts treat hypertension as a risk factor due to its increasing frequency among individuals with other factors, such as obesity and smoking.
Asthma and other inflammation issues, while not widely recognized, appear to be risk factors as well.
Research confirms that chronically elevated blood glucose levels can damage the vascular endothelium and other tissues. This can lead to increased insulin resistance and risk of heart disease.
Medical News Today discussed the present study with Dr. Jagdish Khubchandani, a professor of public health at New Mexico State University, who was not involved in this research.
Dr. Khubchandani agreed that chronic conditions do not just happen in isolation, saying: "Given the volume of evidence on the co-occurrence of these conditions, the findings are not coincidental but more of a syndrome complex."
"Once a person acquires one chronic disease, the likelihood for the occurrence of other chronic conditions increases substantially via multiple pathways. These can be immune, inflammatory, biochemical, or psychological, among the many unknowns."— Dr. Jagdish Khubchandani
"For example, individuals with chronic respiratory illness may have immune dysregulation or chronic inflammation, which may lead to insulin resistance and the development of diabetes. Or, the medications taken to treat chronic respiratory conditions may affect metabolism and lead to diabetes," Dr. Khubchandani further explained.
"Also, oftentimes, individuals with chronic diseases have more stress or are prone to depression and anxiety that are also linked to diabetes — links via unhealthy dietary patterns, poor weight management, etc.," he added.
In their paper, the U.K. Team also cited a 2021 study demonstrating a link between social inequities and "adverse cardiac outcomes" in individuals with type 2 diabetes.
The experts remarked that "[m]easures that reduce social inequality have the potential — in the longer term — to reduce the social gradient in health outcomes described here."
Dr. Khubchandani saw social factors as "one of the major pathways connecting chronic respiratory illness to diabetes or for the risk of developing [type 2 diabetes] alone".
He said that people from historically marginalized groups and those with lower financial and educational resources are more likely to experience chronic respiratory illnesses. Their tendency not to get quality treatment can create a "greater psychosocial burden", which can increase the risk of type 2 diabetes.
"Belonging to a lower income and education group also affects living conditions, knowledge of health-related issues, access to healthy food, and ability to engage in the recommended amounts of physical activity. These can individually be linked to type 2 diabetes without having other chronic conditions. One can assess these from rates of type 2 diabetes in the rural and Southern U.S. Where multiple such disadvantages affect individuals."— Dr. Jagdish Khubchandani
The research team behind this study admits that their sample size was small. However, they hope to extend the study in due time. The analysis also depends on the accuracy of primary care coding data, which could contain errors.
Dr. Heald and his cohort expect that larger population studies, artificial intelligence, and machine learning analytics will help "address […] [the] multifactorial complexity" of interpreting health records for disease patterns.
Type 2 diabetes has multiple subgroups, all of which the researchers could not examine in this study. Moreover, the actual year of type 2 diabetes diagnosis could be several years after the onset of symptoms since early hyperglycemia can be asymptomatic.
Comments
Post a Comment